Munyentwali, Helene <br/><br/>
Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease.  [electronic resource] 

 -  Kidney international  Mar 2013 
 - 511-6 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1523-1755 
<br/><br/><label>Standard No.: </label>10.1038/ki.2012.444  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Antibodies, Monoclonal, Murine-Derived--adverse effects<br/>Antigens, CD19--analysis<br/>Antigens, CD20--immunology<br/>Female<br/>Humans<br/>Immunosuppressive Agents--therapeutic use<br/>Male<br/>Middle Aged<br/>Nephrosis, Lipoid--drug therapy<br/>Prednisone--therapeutic use<br/>Recurrence<br/>Retrospective Studies<br/>Rituximab